SyntekaBio, Inc. (KOSDAQ:226330)
South Korea
· Delayed Price · Currency is KRW 3,220.00
-20.00 (-0.62%)
At close: Apr 28, 2026
SyntekaBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | 3,429 | 120.89 | 123.41 | 243.99 | 316.66 | Upgrade
|
| Revenue Growth (YoY) | 2736.72% | -2.04% | -49.42% | -22.95% | -48.06% | Upgrade
|
| Cost of Revenue | 4.31 | 3.91 | 2.48 | 10.96 | 15.24 | Upgrade
|
| Gross Profit | 3,425 | 116.97 | 120.92 | 233.04 | 301.42 | Upgrade
|
| Selling, General & Admin | 9,863 | 9,253 | 7,477 | 7,456 | 4,828 | Upgrade
|
| Research & Development | 2,290 | 2,937 | 3,225 | 3,177 | 3,101 | Upgrade
|
| Amortization of Goodwill & Intangibles | 100.78 | 101.99 | 181.75 | 148.8 | 111.18 | Upgrade
|
| Other Operating Expenses | 246.62 | 233.5 | 187.25 | 149.85 | 106.24 | Upgrade
|
| Operating Expenses | 14,190 | 14,387 | 12,397 | 12,025 | 9,193 | Upgrade
|
| Operating Income | -10,765 | -14,270 | -12,276 | -11,792 | -8,891 | Upgrade
|
| Interest Expense | -2,841 | -2,008 | -375.74 | -1,251 | -254.17 | Upgrade
|
| Interest & Investment Income | 26.73 | 349.12 | 1,171 | 971.76 | 374.41 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.13 | -8.39 | -0.35 | 2.59 | 0.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 720.52 | 8,895 | 758.7 | 7,583 | -6,032 | Upgrade
|
| EBT Excluding Unusual Items | -12,855 | -7,042 | -10,723 | -4,486 | -14,803 | Upgrade
|
| Gain (Loss) on Sale of Assets | -25.27 | -5.73 | - | 0.13 | - | Upgrade
|
| Asset Writedown | -46.91 | -1.26 | -72 | -20.25 | - | Upgrade
|
| Other Unusual Items | -4,450 | -163.97 | -603.08 | - | - | Upgrade
|
| Pretax Income | -17,378 | -7,213 | -11,398 | -4,506 | -14,803 | Upgrade
|
| Net Income | -17,378 | -7,213 | -11,398 | -4,506 | -14,803 | Upgrade
|
| Net Income to Common | -17,378 | -7,213 | -11,398 | -4,506 | -14,803 | Upgrade
|
| Shares Outstanding (Basic) | 16 | 15 | 14 | 14 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 15 | 14 | 14 | 13 | Upgrade
|
| Shares Change (YoY) | 2.20% | 6.52% | 5.94% | 0.37% | 1.65% | Upgrade
|
| EPS (Basic) | -1115.00 | -473.00 | -796.14 | -333.47 | -1099.43 | Upgrade
|
| EPS (Diluted) | -1115.00 | -473.00 | -796.14 | -333.47 | -1099.43 | Upgrade
|
| Free Cash Flow | -10,661 | -16,216 | -17,442 | -16,899 | -13,520 | Upgrade
|
| Free Cash Flow Per Share | -684.02 | -1063.33 | -1218.35 | -1250.52 | -1004.13 | Upgrade
|
| Gross Margin | 99.87% | 96.76% | 97.99% | 95.51% | 95.19% | Upgrade
|
| Operating Margin | -313.91% | -11804.01% | -9947.91% | -4832.99% | -2807.83% | Upgrade
|
| Profit Margin | -506.76% | -5966.88% | -9235.91% | -1846.96% | -4674.69% | Upgrade
|
| Free Cash Flow Margin | -310.88% | -13413.89% | -14133.89% | -6926.24% | -4269.46% | Upgrade
|
| EBITDA | -8,741 | -12,015 | -10,514 | -10,319 | -7,733 | Upgrade
|
| EBITDA Margin | -254.90% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2,023 | 2,254 | 1,762 | 1,473 | 1,158 | Upgrade
|
| EBIT | -10,765 | -14,270 | -12,276 | -11,792 | -8,891 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.